Vogkare M 0.2 Tablet

Oral tablet. Usually taken with meals as prescribed; voglibose-containing combinations are typically taken just before the first bite of a main meal. Swallow whole with water; do not skip meals. Dose and frequency depend on blood sugar control and kidney function.

Voglibose is an alpha-glucosidase inhibitor that delays intestinal carbohydrate digestion and absorption, reducing post-meal blood sugar spikes. Metformin decreases hepatic glucose production and improves insulin sensitivity, helping lower fasting and postprandial glucose.

Risk of hypoglycaemia increases if used with insulin or sulfonylureas; monitor glucose. Metformin may rarely cause lactic acidosis—risk increases with kidney impairment, dehydration, severe infection, heart/respiratory failure, liver disease, heavy alcohol use; stop and seek care if rapid breathing, severe weakness, abdominal pain occur. Avoid in severe renal impairment; periodic renal function monitoring required. Temporarily withhold metformin around iodinated contrast studies and major surgery as advised by a doctor. Voglibose may cause GI discomfort; titrate as directed.

Alcohol (increases lactic acidosis risk with metformin), iodinated contrast media, carbonic anhydrase inhibitors (e.g., topiramate/acetazolamide), cimetidine, diuretics, corticosteroids, thyroid hormones, beta-agonists, insulin and sulfonylureas (increased hypoglycaemia risk)

Store below 25°C in a cool, dry place. Protect from moisture and light. Keep out of reach of children.

Voglibose 0.2 mg + Metformin tablets (other brands), Vobit-M 0.2 Tablet, Voglib M 0.2 Tablet, Volibo M 0.2 Tablet, Vogmet 0.2 Tablet